MedTrace Logo

Effect of Trimetazidine on Endothelin-1 and Clinical Outcomes of Patients With Diabetic Peripheral Neuropathy

NCT07794475 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-08-31

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate if trimetazidine can improve clinical outcomes of patients with diabetic peripheral neuropathy. The main questions it aims to answer are:

Does trimetazidine improve the symptoms of diabetic peripheral neuropathy? Does trimetazidine affect endothelin-1 levels?

Participants in the interventional arm will receive trimetazidine tablets 35 mg twice daily for three months.

Conditions

  • Diabetic Peripheral Neuropathic Pain (DPN)

Interventions

DRUG

Trimetazidine Dihydrochloride Tablets

trimetazidine 35 mg oral tablets twice daily

Sponsors & Collaborators

  • Sara Refaat Azab Metry

    lead OTHER

Principal Investigators

  • Lamia El Wakeel, PhD · Faculty of Pharmacy, Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07794475 on ClinicalTrials.gov